• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.

作者信息

Sherry A D, Lin T A, McCaw Z R, Ludmir E B

机构信息

Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore.

出版信息

Ann Oncol. 2024 Aug;35(8):747-748. doi: 10.1016/j.annonc.2024.05.543. Epub 2024 Jun 3.

DOI:10.1016/j.annonc.2024.05.543
PMID:38838846
Abstract
摘要

相似文献

1
Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.
Ann Oncol. 2024 Aug;35(8):747-748. doi: 10.1016/j.annonc.2024.05.543. Epub 2024 Jun 3.
2
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3.
3
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.阿贝西利联合非甾体芳香化酶抑制剂作为 HR+/HER2-晚期乳腺癌的初始治疗：MONARCH 3 的最终总生存结果。
Ann Oncol. 2024 Aug;35(8):718-727. doi: 10.1016/j.annonc.2024.04.013. Epub 2024 May 8.
4
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.阿贝西利联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性的绝经前激素受体阳性晚期乳腺癌：MONARCH 2 试验的亚组分析。
Breast Cancer Res. 2021 Aug 23;23(1):87. doi: 10.1186/s13058-021-01463-2.
5
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.MONARCH 3 研究：阿贝西利联合芳香化酶抑制剂作为 HR+/HER2-晚期乳腺癌初始内分泌治疗的疗效和安全性
Oncologist. 2020 Sep;25(9):e1346-e1354. doi: 10.1634/theoncologist.2020-0084. Epub 2020 Jun 24.
6
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.阿贝西利联合曲妥珠单抗和（或）氟维司群对比曲妥珠单抗联合标准治疗化疗用于激素受体阳性、HER2 阳性晚期乳腺癌患者（monarcHER）：一项随机、开放标签、二期临床试验。
Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27.
7
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.阿贝西利单药或联合内分泌治疗晚期乳腺癌患者循环肿瘤 DNA 中基线和获得性基因组改变的图谱。
Clin Cancer Res. 2024 May 15;30(10):2233-2244. doi: 10.1158/1078-0432.CCR-22-3573.
8
Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.阿贝西利联合内分泌治疗对比化疗用于 HR+/HER2-转移性乳腺癌患者既往帕博西利进展后的治疗：中国单中心真实世界研究。
Cancer Med. 2024 May;13(10):e7249. doi: 10.1002/cam4.7249.
9
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.MONARCH 3：阿贝西利作为晚期乳腺癌初始治疗。
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
10
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.在中国绝经前和绝经后女性中，初始使用瑞博西尼联合内分泌治疗HR+/HER2-晚期乳腺癌：一项2期随机研究的主要结果
Cancer Med. 2024 Aug;13(15):e7408. doi: 10.1002/cam4.7408.